Key Highlights

  • Surgery Partners shares are trading at $13.27 in Thursday's session, down 4.31%.
  • A brokerage reiterated an Outperform rating with a $19 target, calling the Idaho Falls divestiture the company's most significant strategic move this year.
  • The sale sharpens the company's focus as an outpatient surgical platform and improves earnings-to-cash conversion.
  • Insider net selling and ongoing unprofitability weigh on sentiment as the shares sit about 43% below their 52-week high.

A Praised Divestiture Cannot Offset Rate Pressure

Surgery Partners (NASDAQ:SGRY) is moving lower in Thursday's session as investors weigh its Idaho Falls divestiture against a stretched share price and a backdrop of rising yields. The Brentwood, Tennessee-based company, majority-owned by Bain Capital, operates a nationwide network of more than 200 short-stay surgical facilities, including ambulatory surgery centers and surgical hospitals.

The shares are trading near $13.27, down 4.31%, on light volume, after a decline of roughly 3.8% in the prior session. Wall Street is softer at the start of the fourth quarter, Treasury yields sit near multi-decade highs and the broader healthcare sector is lower.

Why a Brokerage Calls the Sale a Strategic Win

A brokerage reiterated its Outperform rating and $19 target, describing the Idaho Falls sale as the company's most significant strategic move this year. The firm argued it sharpens Surgery Partners' focus as an outpatient surgical platform and improves earnings-to-cash conversion.

Insider Selling and Thin Profitability Weigh on Sentiment

Insider net selling and ongoing unprofitability continue to weigh on the stock, which trades at a forward Earnings multiple near 28 times. The shares are about 43% below their 52-week high of $23.44 and roughly 16% above the 52-week low of $11.41.